Beijing: Moderna, the top American pharmaceutical and biotechnology conglomorate located in Cambridge, reported on Wednesday that clinical trials of a booster dosage of a vaccine developed particularly to combat the Omicron variant of COVID-19 had begun.
According to cable News Network, , the trials will involve 600 adults and will take place at up to 24 locations across the United States. Some participants will have had two doses of Moderna's vaccine and others will have had a booster shot.
"The antibody persistence against Omicron six months following the currently approved 50 mg booster of mRNA-1273 reassures us. Nonetheless, given Omicron's long-term threat, we're moving forward with our Omicron-specific variant vaccine booster candidate, and we're excited to start this phase of our Phase 2 trial "source quoted on CEO Stephane Bancel's statement.
"We're also considering whether this Omicron-specific candidate should be included in our multivalent booster programme," it added.
Novavax: Australia's fifth approved COVID-19 vaccine
